Back to article: Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy

FIGURE 1: Graphical representation of MEKi/CD40 Ab antitumor mechanism. MEKi can play a dual role in anti-tumor immune responses by inducing immunogenic cell death of tumor cells and by eliminating immunosuppressive immune cells in the TME, in particular T-regulatory cells, M2-type macrophages and MDSCs. Agonist anti-CD40 provides co-stimulatory signal, increases antigen presentation, and stimulates CD4+ and CD8+ T cells. These complementary drug actions exert synergistic T cell-dependent anti-tumor effects. Figure created with

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.